Skip to Content
  • Two Diabetes Drug Mysteries

    Here are some data to file under “Drugs do things that we don’t expect”. The SGLT-2 inhibitors are a class of diabetes medications that work b… Read More
  • Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you… Read More
  • A Look at Antibody Therapies

    Since we were just talking about antibody therapies in immuno-oncology, here’s a timely column by Bruce Booth at LifeSciVC on antibody therapies in genera… Read More
  • Turmoil in Immuno-oncology

    Immuno-oncology! It’s such a big deal, let’s just do what everyone in the field is doing and call it “IO”. The recent successes in this… Read More
  • There Are Failures, You Know

    This exact point came up around here when we last discussed FDA reform, so it’s good to see it made at length in the New England Journal of Medicine. Reme… Read More
  • Kite’s Latest News

    Readers will surely recall the problems that surfaced last year with Juno’s CAR-T cell therapy program. There were a number of patient deaths, and worried… Read More
Page 1 of 4512345...102030...Last »